Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
rosacea eczema alopecia ceramide keratosis pityriasis basal cell melanoma keratosis purpuraYour Article Summary
See Latest ArticlesGood Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report-Part III
Value in Health, 10/29/09
Carroll NV et al. – Estimates of drug cost from the MCO perspective should include amounts paid for medication ingredients and dispensing fees, and net out copays, rebates, and other drug price reductions. Because of the evolving nature of drug pricing, ISPOR should publish a Web site where current DCTF costing recommendations are updated as new information becomes available.
Related Articles
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations
Value in Health, 11/11/09
Relevance Score: 71%
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report-Part VI
Value in Health, 10/29/09
Relevance Score: 71%
Value-Based Insurance Design in Medicare
Applied Health Economics and Health Policy, 10/20/09
Relevance Score: 70%
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective: The ISPOR Drug Cost Task Force Report-Part V
Value in Health, 10/29/09
Relevance Score: 69%
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report-Part IV
Value in Health, 10/19/09
Relevance Score: 69%
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Cost Effectiveness of Etoricoxib versus Celecoxib and Non-Selective NSAIDS in the Treatment of Ankylosing Spondylitis
PharmacoEconomics, 03/16/10
Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren
European Journal of Clinical Pharmacology, 03/16/10
Does the Funding Source Influence the Results in Economic Evaluations?: A Case Study in Bisphosphonates for the Treatment of Osteoporosis
PharmacoEconomics, 03/15/10
Article Search
Sponsor
Sponsor